JMP Securities analyst Konstantinos Aprilakis maintained a Buy rating on Compugen Ltd (NASDAQ: CGEN) on October 12 and set a price target of $11. The company’s shares closed yesterday at $3.55.
According to TipRanks.com, Aprilakis has 0 stars on 0-5 star ranking scale with an average return of -13.8% and a 25.0% success rate. Aprilakis covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Concert Pharma, and AnaptysBio Inc.
Currently, the analyst consensus on Compugen Ltd is a Moderate Buy with an average price target of $10, representing a 181.7% upside. In a report issued on October 11, Oppenheimer also reiterated a Buy rating on the stock with a $9 price target.
.
See today’s analyst top recommended stocks >>
Based on Compugen Ltd’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $10.19 million. In comparison, last year the company had a GAAP net loss of $9.87 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases.
